anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

187,741-187,800 of 319,975

filter-aware
10
Includes waterfall plot for partial response and spider plot for longitudinal tumor change.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
11
The slide uses a process-flow diagram to map patient cohorts to clinical outcomes and subsequent study advancement decisions.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
12
Includes a spider plot for lesion change and a Kaplan-Meier survival curve.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
13
Includes Kaplan-Meier survival curve and waterfall plot for lesion change.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
14
Clinical trial data showing PFS at 3 months for Liposarcoma and Synovial Sarcoma cohorts.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
15
Includes specific clinical trial terminology (CTCAE, SAE, RP2D, Q2W).BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
16
The slide uses a grid of metrics to establish the total addressable market and clinical benchmarks.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Quick Win Big Bet1 hit
17
The chart is a waterfall plot showing maximum change from baseline for different patient cohorts.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
18
The slide uses a process-oriented layout to describe clinical trial phases.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
19
Clinical trial data for BA3011 in NSCLC patients.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
20
Clinical trial data presentation for oncology drug candidate.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
21
The slide serves as a section divider for a deep dive into a specific therapeutic platform.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
22
The slide uses a grid of metrics to define the total addressable market and the specific target segment.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
23
The chart is a waterfall plot showing percentage change in tumor size for individual patients.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
24
The slide uses a 2x2 grid of metrics to frame the market problem, followed by specific target population and success threshold data.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
25
The chart displays longitudinal data for two specific patients, showing sustained complete response.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
26
SCCHN = Squamous Cell Carcinoma of the Head and Neck. ROR2 is the target biomarker.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
27
The slide uses a table to present clinical outcomes for specific tumor types, emphasizing the first-in-class potential of the therapy.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
28
The slide uses a process-oriented layout to describe clinical trial phases.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
29
BioAtla | Investor Presentation Deck | 37 slidesBioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
30
The slide uses a combination of a comparison table for clinical data and a dot plot for NHP toxicity data.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
31
The slide uses a timeline-based visual to show dose escalation steps leading to RP2D selection.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
32
BioAtla | Investor Presentation Deck | 37 slidesBioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
33
The chart shows tumor volume over time for three different antibody treatments, with the CAB-EpCAM x CAB-CD3 showing the best efficacy.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
34
The slide uses a timeline-based table structure to map programs to specific clinical milestones.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations Loop · Why Now1 hit
35
Uses a linked-circle diagram to represent interconnected business pillars.BioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
36
BioAtla | Investor Presentation Deck | 37 slidesBioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
37
BioAtla | Investor Presentation Deck | 37 slidesBioAtla | Investor Presentation Deck | 37 slides · BioAtla
Pitch deck Investor relations 1 hit
01
Slide 1
BioNTech | Investor Presentation Deck | 28 slidesBioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations 1 hit
02
BioNTech | Investor Presentation Deck | 28 slidesBioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations 1 hit
03
Standard pharmaceutical regulatory disclosure slide.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations 1 hit
04
Standard pharmaceutical regulatory disclosure slide.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations 1 hit
05
Standard pharmaceutical safety disclosure slide.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations 1 hit
06
BioNTech | Investor Presentation Deck | 28 slidesBioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · ProblemLoop · Golden Circle1 hit
07
The slide uses a semi-circular layout to represent the company's strategic pillars.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · ProblemLoop · Golden Circle1 hit
08
The slide uses a structured grid layout to categorize key performance indicators.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Loop · Golden Circle1 hit
09
The slide uses a list-based timeline/milestone format to highlight growth across five key areas.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Loop · Golden Circle1 hit
10
The slide highlights organizational scale and diversity metrics as of Dec 31, 2021.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Loop · Golden Circle1 hit
11
The slide uses a structured layout to present four pillars of corporate social responsibility.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Loop · Golden Circle1 hit
12
The slide categorizes partnerships into clinical stage and pre-clinical programs, detailing the nature of the collaboration (e.g., cost/profit share, royalties).BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Loop · Golden Circle1 hit
13
BioNTech | Investor Presentation Deck | 28 slidesBioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
14
The diagram uses a hexagonal grid to represent different technology platforms and their development status/origin.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
15
BioNTech | Investor Presentation Deck | 28 slidesBioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Loop · Golden Circle1 hit
16
Uses a temporal progression layout (Today -> Mid-term -> Long-term).BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
17
Includes product image and key performance metrics.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
18
Slide highlights both historical traction (>3.6bn doses) and future growth vectors (label expansion, boosters, next-gen vaccines).BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
19
The slide uses a two-column layout to contrast the 'why' (medical need) with the 'how' (technologies).BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · ProductLoop · Golden Circle1 hit
20
The chart uses a horizontal bar representation to indicate the clinical stage of each program.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · ProductLoop · Golden Circle1 hit
21
The diagram illustrates a circular, iterative process (flywheel) connecting patient samples and variability to specific drug classes.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · ProductLoop · Golden Circle1 hit
22
The slide uses a hub-and-spoke diagram to show how various modalities converge on patient care.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · ProductLoop · Golden Circle1 hit
23
The slide uses a Gantt-style visualization to show clinical trial phases for various drug candidates.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · ProductLoop · Golden Circle1 hit
24
The slide uses a matrix structure to compare different drug development programs.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · ProductLoop · Golden Circle1 hit
25
BioNTech | Investor Presentation Deck | 28 slidesBioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · The AskLoop · Golden Circle1 hit
26
The slide uses a grouped table structure to categorize milestones by therapeutic area (COVID-19, Infectious Disease, Oncology, Data Updates).BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · The AskLoop · Golden Circle1 hit
27
The slide uses a column-based layout to categorize strategic initiatives, with a footer highlighting foundational enablers.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Beat · The AskLoop · Golden Circle1 hit
28
This is a standard corporate contact/footer slide.BioNTech | Investor Presentation Deck | 28 slides · BioNTech
Pitch deck Investor relations Loop · Golden Circle1 hit
01
Slide 1
BioNTech | Results Presentation Deck | 32 slidesBioNTech | Results Presentation Deck | 32 slides · BioNTech
Conference presentation Investor relations 1 hit
02
BioNTech | Results Presentation Deck | 32 slidesBioNTech | Results Presentation Deck | 32 slides · BioNTech
Conference presentation Investor relations 1 hit
03
This is a standard pharmaceutical regulatory disclosure slide.BioNTech | Results Presentation Deck | 32 slides · BioNTech
Conference presentation Investor relations 1 hit
04
Standard pharmaceutical regulatory disclosure slide.BioNTech | Results Presentation Deck | 32 slides · BioNTech
Conference presentation Investor relations 1 hit